FDA’s Jenkins On “Progressive Approval”: Don’t Lower The Efficacy Bar

Office of New Drugs director says a “weight of the evidence” standard will not provide reasonable assurance of drug efficacy and safety.

There are plenty of unknowns surrounding the concept of a “progressive approval” system, but one thing is clear in the eyes of FDA Office of New Drugs Director John Jenkins – there should be no lowering of the efficacy bar.

During a panel discussion at Elsevier Business Intelligence’s FDA/CMS Summit on Dec. 8, Jenkins was asked to comment on proposals for new approval pathways that would speed the development and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approval Standards

More from Pathways & Standards

Drug, Biologic Policy Staff Return To US FDA, As RIF Process Hangs In Legal Limbo

 

The FDA employees with reduction-in-force notice rescissions include some who work on user fee negotiations, but staff still subject to RIFs will not officially separate from the agency this week due to ongoing legal challenges.

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

What Information Does US FDA Need For Stealth’s Elamipretide After CRL?

 
• By 

The agency said it will consider knee extensor muscle strength as a potential intermediate clinical endpoint to support accelerated approval, but Stealth CEO Reenie McCarthy said announcing it via complete response letter is confusing and inefficient.